Drugs / CMV-pp65 CTLs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01646645 | Jul 2012 → Dec 2019 | cytomegalovirus infection | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMV-pp65 CTLs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01646645 ↗ |
| Modality | Cell therapy | “The T-cells to be infused” NCT01646645 ↗ |
| Route | Intravenous | “T-cells will be administered by bolus intravenous infusion” NCT01646645 ↗ |